Literature DB >> 8048439

Assessing the adequacy of vascular access and its relationship to patient outcome.

S J Schwab1.   

Abstract

Hemodialysis requires repeated reliable access to blood vessels capable of providing rapid extracorporeal blood flow. This access to the circulation, termed "vascular access," is currently met by the use of native and synthetic arteriovenous fistulas. Vascular access dysfunction is a leading cause of hemodialysis morbidity and a major contributor to hemodialysis cost. Fistula thromboses and infection are the two leading causes of access failure. This report describes what constitutes adequate vascular access and outlines techniques for decreasing vascular access morbidity. New concepts for dialysis unit-based quality assurance focusing on prevention of access thromboses and infection are emphasized as a means of improving patient outcome. Research initiatives seeking to minimize access complications are proposed.

Entities:  

Mesh:

Year:  1994        PMID: 8048439     DOI: 10.1016/s0272-6386(12)80197-1

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  4 in total

1.  Clinical and Regulatory Considerations for Central Venous Catheters for Hemodialysis.

Authors:  Douglas M Silverstein; Scott O Trerotola; Timothy Clark; Garth James; Wing Ng; Amy Dwyer; Marius C Florescu; Roman Shingarev; Stephen R Ash
Journal:  Clin J Am Soc Nephrol       Date:  2018-10-11       Impact factor: 8.237

Review 2.  Vascular access for hemodialysis: postoperative evaluation and function monitoring.

Authors:  Konstantinos Leivaditis; Stelios Panagoutsos; Athanasios Roumeliotis; Vassilios Liakopoulos; Vassilis Vargemezis
Journal:  Int Urol Nephrol       Date:  2013-09-18       Impact factor: 2.370

Review 3.  Vascular access in elderly patients with end-stage renal disease.

Authors:  Nikolaos Bessias; Kosmas I Paraskevas; Effie Tziviskou; Vassilios Andrikopoulos
Journal:  Int Urol Nephrol       Date:  2008-09-16       Impact factor: 2.370

4.  General health of end stage renal disease program beneficiaries.

Authors:  R J Ozminkowski; A J White; A Hassol; M Murphy
Journal:  Health Care Financ Rev       Date:  1997
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.